Hyderabad: Optimus, which has completed molnupiravir oral capsule phase 3 clinical trial, has applied for emergency use authorization (EUA) for the drug with the Drugs Controller General of India (DCGI). On May 18, 2021, the Hyderabad-based company received approval from the DCGI to conduct the phase 3 trial as per the recommendations of the […]
Hyderabad: Hyderabad-based Optimus Pharma has received tentative approval from the United States Food and Drug Administration (FDA) for the generic equivalent of Rexulti Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, of Otsuka Pharmaceutical. Brexpiprazole tablets will be manufactured at Optimus Pharma’s Pashamylaram USFDA accredited facility in India. The […]
